The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
Shanghai Moyom Biotechnology has obtained a Class III Medical Device Certificate from the China National Medical Products Administration (NMPA 20253130390) for its Aphranel MagiCCrystal CaHA filler.
The company says this makes it the first calcium hydroxylapatite microsphere (CaHA) injectable product approved in China for facial soft tissue augmentation. CaHA microspheres have become a core material in the global biostimulating injection field due to their biocompatibility and biodegradability, the company notes in a release.ย
Leveraging proprietary technology, Moyom has controlled CaHA microsphere size (30-35ฮผm), through-hole structure, and degradation rate to develop the Aphranel MagiCCrystal CaHA filler. โIts raspberry-like through-hole design increases porosity by 40%, with the number of microspheres per unit volume exceeding six times that of competing product. The viscoelastic modulus (G’ value) reaches 5500Pa, enabling long-lasting 3D supporting effect,โ according to a release from the company.
The product employs a pre-mixing technology combining CaHA and carboxymethyl cellulose to ensure uniform particle suspension and a smoother injection push force. Validated by 31 biochemical tests, its inflammation rate is 30% lower than leading standards, and it is fully biodegradable. Its safety has been certified by Notified bodies in the EU, Brazil, Russia, Saudi Arabia, Mexico, and other countries.
“We are committed to providing safer and more accessible products for the global medical aesthetics market through technological innovation and promoting the sustainable development of the industry,”ย according to a release from the company.
Photo caption: Aphranel MagiCCrystal CaHA filler
Photo credit: Shanghai Moyom Biotechnology
